|
September 2007
STADA acquires Forum Bioscience
On 21 September 2007, STADA Arzneimittel completed the acquisition of Forum Bioscience Holdings Limited which includes Britannia Pharmaceuticals Limited.
For further information, please see the following STADA press releases:
31 August 2007, 21 September 2007
February
2007
Britannia announces the launch of Opizone
To add to its addictions field portfolio, Britannia has
launched Opizone (naltrexone hydrochloride 50mg tablet). Opizone blocks the
euphoric effects of opioids, minimising the positive rewards that play
a large part in craving and relapse and so is used post detox. For further
information, please contact us.
April 2006
Britannia signs agreement with BioTie to market and distribute nalmefene
in the UK and Ireland
Click
here
to view a press release.
February 2006
Britannia and Kyowa Hakko Kogyo announce agreement, out-licensing apomorphine pen in Japan
Click
here
to view a press release.
November 2005
Collaboration with Vernalis for other
apomorphine presentations in
North America
Click
here
to view a press release.
November 2005
Britannia's new licensee for apomorphine in North America
Click
here
to view a press release.
October 2005
APO-go in Australia
Britannia signs an agreement with Mayne Pharma in Australia, for the
distribution of APO-go Pre-filled Syringe®
used in the treatment of Parkinson's disease.
December 2004
Britannia announces the launch of the APO-go Pre-filled Syringe
To complement its range of apomorphine therapy, Britannia Pharmaceuticals
has launched the APO-go 5mg/ml Solution for Infusion in Pre-filled
Syringe, designed for use in continuous infusion treatment. For further
information, please contact us.
November 2004
AirPharma signs
agreement with Britannia to bring novel asthma
treatment to market
Click
here
for a copy of Britannia's press release.
(33
KB)
September 2004
Britannia expands nasal powder program with new production capability
Click
here
for a copy of Britannia's press release.
(38
KB)
November 2003
Britannia signs agreement with US WorldMeds to bring first non-opiate drug
addiction treatment to the US
Click
here
for a copy of Britannia's press release.
(29
KB)
October 2003
Britannia and Bespak to advance development and commercialisation of
surgical adhesions treatment
Click
here
for a copy of Britannia's press release.
(32
KB)
September 2003
Britannia and
Novartis collaborate to develop nasal powder treatment for migraines
Click
here
for a copy of Britannia's press release.
(31
KB)
August 2003
Top medical providers to discuss the role of apomorphine in the management
of late-stage Parkinson’s disease
Click
here
for a copy of Britannia's press release
.
(24
KB)
June 2003
New study shows the
potential of BritLofex in preventing opiate relapse
Click
here
for a copy of Britannia's press release.
(55
KB)
June 2003
ERJ publishes exciting
asthma trial for pumactant
Click
here
for a copy of Britannia's press release.
(56
KB)
April 2003
Survey of surgeons reveals the extent of the adhesions problem and
dissatisfaction with current treatments
Click here for a copy
of Britannia's press release.
(58
KB)
October 2002
Britannia Pharmaceuticals to develop nasal powder treatment for
migraine sufferers
Click here for a copy of
Britannia's press release.
(26 KB)
October 2002
Pharma Marketletter reviews Britannia's development programme
Click here to view a
PDF copy.
(854 KB)
September 2002
Britannia is profiled in Scrip Magazine
Click here to view a
PDF copy.
(1.39 MB)
July 2002
Britannia is featured in Scrip's Target, World Drug Delivery News
Scrip's Target reviews Britannia's development of apomorphine nasal powder
for male erectile dysfunction. Click
here to view a PDF copy.
(370KB)
June 2002
Scrip World Pharmaceutical News reviews Britannia's development programme
Click here to view a PDF copy.
(349 KB)
June 2002
Trial of
Britannia Pharmaceuticals’ BritLofex® stopped
early due to overwhelming efficacy
Click
here
for a copy of Britannia's press release.
(47KB)
June 2002
Britannia Pharmaceuticals to launch Erectile Dysfunction trials with Apomorphine
Nasal Powder
Click
here for a copy of Britannia'a press release.
(41
KB)
May 2002
New trial demonstrates striking results of Britannia Pharmaceuticals’
new asthma treatment
Click
here for a copy of Britannia's press release.
(56
KB)
May 2002
Britannia announces the launch of the APO-go Pen
To complete the relaunch of its
apomorphine injection range, which began with the introduction of APO-go
ampoules, Britannia is now replacing its Britaject Pen with the APO-go
Pen.
April 2002
Britannia Pharmaceuticals launches surgical adhesion trials with AdSurf®
Click here for a copy of
Britannia's press release.
(57
KB)
April 2002
Britannia is featured in PharmaVoice
Britannia's
proprietary nasal delivery powder technology is described in the April
2002 edition of PharmaVoice. Click
here to view a PDF copy.
(290 KB)
November 2001
Lofexidine website launch
Britannia launches a dedicated website containing information on BritLofex (lofexidine hydrochloride) and its use in opiate
detoxification.
www.lofexidine.co.uk
April 2001
Apomorphine website launch
Britannia launches www.apomorphine.co.uk,
a dedicated web site containing information on apomorphine
therapy aimed at assisting Parkinson's disease patients.
If you require further
information on any of the above, please contact us. |
